• Munther Khamashta and HughesGraham R VGRVEmeritus Professor of Rheumatology, King's College London, The London Lupus & Rheumatology Centre, London, United Kingdom..
• Emeritus Professor of Medicine, King's College London, GSK Global Medical Expert-Lupus, Dubai, United Arab Emirates. Electronic address: munther.a.khamashta@gsk.com.
• Med Clin (Barc). 2024 Aug 1; 163 Suppl 1: S1S3S1-S3.

AbstractIn the 40 years since the original detailed description of antiphospholipid syndrome (APS), the condition has come to be regarded as one of the most common autoimmune diseases. The impact of the description has been enormous - for example, the recognition that some individuals with connective tissue diseases require anticoagulation rather than corticosteroids or anti-inflammatory treatment has bought about fundamental change in medical practice. In obstetrics, APS is now regarded as the most important prothrombotic cause of recurrent pregnancy loss - with pregnancy success improving from below 20% to current live birth rate over 80%. In neurology, APS may be associated with up to 20% of strokes in people under 40 - a striking figure not least in terms of medical economics, let alone in potentially preventable suffering. In vascular medicine, APS links immunology with thrombosis and vascular disease and may well provide insights into immunological factors in the pathogenesis of atherosclerosis.Copyright © 2024 Elsevier España, S.L.U. All rights reserved.

17 keywords...

hide…